PLENARY SPEAKER
Title: Discovery of Nitric Oxide and Cyclic GMP in Cell Signaling and Their Role in Drug Discovery and Development
Dr. Ferid Murad, M.D.
1998 Nobel Laureate in Physiology and Medicine
Lasker Awardee for Basic Research in Medicine
Professor in the Department of Biochemistry and Molecular Biology
George Washington University
Washington DC, USA
MEETING ORGANIZER
Dr. Harold C. Smith, Ph.D
Conference Chairman - Drug Discovery 2018
Department of Biochemistry and Biophysics
University of Rochester, School of Medicine and Dentistry, NY, USA
Fellow of the Royal Society of Biology
Founder and CEO, OyaGen, Inc, NY, USA
KEYNOTE SPEAKERS
Wendy Cornell, Ph.D.
Manager Drug Discovery Technologies (YKT)IBM - Healthcare and Life Sciences Research, USA
Title: AI in Drug Target Identification and Drug Discovery
Troels Koch, Ph.D.
VP & Head of Research, RNA TherapeuticsRoche Innovation Center Copenhagen, Denmark
Title: New Drug Discovery Concepts for Locked Nucleic Acid (LNA) Therapeutics
Philip S. Low, Ph.D.
Presidential Scholar for Drug DiscoveryPurdue University, IN, USA
Title: Sensitive Control of CAR T Cell Properties with Low Molecular Weight Drugs
Dawei Li, Ph.D.
Shanghai Jiao Tong University, ChinaTitle: Antibody Targeting of the Tumor Tissue Signalling in Solid Tumors
SYMPOSIUM SPEAKERS
Michelle Arkin, Ph.D.
Co-director, Small Molecule Discovery Center (SMDC), San Francisco, CA, USATitle: A Consortium-Based Approach to Academic Drug Discovery
Hashim M Al-Hashi, Ph.D.
Director, Duke Center for RNA Biology, Duke University, NC, USATitle: Dynamic Ensemble-based Discovery of Small Molecules Targeting RNA
Sabah Akrawi, Ph.D.
College of Clinical Pharmacy, King Faisal University, Al-Ahsa, KSATitle: Dynamic Ensemble-based Discovery of Small Molecules Targeting RNA
Ryan Bennett, Ph.D.
Chief Scientific Officer, OyaGen, Inc., Rochester NY, USATitle: Drug Development Utilizing Targets within an Interactome
Jadwiga Bienkowska, Ph.D.
Oncology Translational Research, Pfizer, ORD, San Diego, CA, USATitle: Watson Analytics: AI Research Assistant for Drug Discovery in Oncology
Christine Brideau, Ph.D.
Vice President, In Vitro Biology, Research Service Division (RSD), WuXi AppTec, NJ, USATitle: Perspectives on building effective partnerships between CROs and Academia
Paul S. Brookes, Ph.D.
University of Rochester School of Medicine and Dentistry, NY, USATitle: Role of Mitochondrial Complex II in Cardiac Ischemia, and Optimizing its Inhibition for Therapeutic Benefit
Suguna Rachakonda, Ph.D.
Senior Director, Product Development -Therapeutics, Cleveland Clinic, Cleveland, OH, USATitle: Transforming Academic Drug Discovery Through Novel Public-Private-Partnerships
Thomas D.Y. Chung, Ph.D.
Director, Translational Programs Outreach, SBP Medical Discovery Institute, CA USATitle: Accelerating Translational Research into Drug Discovery in Academia through Strategic Partnerships
Dirk Daelemans, Ph.D.
KU Leuven, Rega InstituteBelgium
Title: Target deconvolution of small-molecules by CRISPR/Cas-mediated resistance mutagenesis scanning
Erkang Fan
University of Washington,Seattle, USA
Title: Targeting methionyl tRNA synthetase for antiparasitic drug discovery
Jennifer E. Golden, Ph.D.
University of Wisconsin-Madison, WI, USATitle: Design and Development of First-In-Class Encephalitic Alphavirus Inhibitors with Prophylactic and Therapeutic In Vivo Efficacy
Rocco G. Gogliotti, Ph.D.
Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, TN, USATitle: Cross-species expression profiling for improved target selection in Rett syndrome
Stine Jørgensen, Ph.D.
Senior Scientist, Vipergen ApS, DenmarkTitle: Nanomolar inhibitor for hexamer DNA helicase RuvBL1/2 identified in DEL screen
Ailong Ke, Ph.D.
Department of Molecular Biology and Genetics, Cornell University, NY, USATitle: Structure,mechanism, and potential applications of the Type I CRISPR-Cas system
Juergen Lademann, Ph.D.
Professor of Dermatology, Head - CCP, Berlin, GermanyTitle: Drug Delivery with Nanoparticles – Science Fiction or Reality
Eric Martin, Ph.D.
Director, Computational Chemistry, Novartis Institutes for BioMedical Research, Inc., CA, USATitle: Massively Multi-Target Profile-QSAR 2.0: Predictions as accurate as 4-point IC50s for most Novartis Assays
Hamid Mirzaei, Ph.D.
UT Southwestern Medical CenterTX, USA
Title: Hydralazine: A FDA Approved Drug with Multiple Therapeutic Targets
Howard Maibach, M.D.
Professor, UCSF School of Medicine, San Francisco, CA, USATitle: Innovation from Academic Dermatology
Mo Mandegar
Tenaya Therapeutics, South San Francisco, CA, USATitle: High-Throughput Drug Discovery Using Artificial Intelligence
Adnan Mannan, Ph.D.
Curtin Health Innovation Research Institute, Curtin University, AustraliaTitle: Investigation of the molecular signalling pathways delivering glucose-lowering effect of Teucrium polium
Shadab Mohammad, Ph.D.
King George’s Medical University, IndiaTitle: Therapeutic Interventions in Oral Submucous Fibrosis: An Experimental and Clinical Study
Elliott Nickbarg, Ph.D.
Merck Research Laboratories, Boston, MA, USATitle: Investigating Non-coding RNAs as Small Molecule Drug Targets using Afinity-Selection Mass Spectrometry
Stephanie C. Oestreich, MPA
EVP, Head BRIDGEs Partnerships North America, EvotecTitle: Bridging the Drug Discovery Gap
Reem Al Olaby, Ph.D.
College of Health Sciences, California Northstate University, CA, USATitle: Ligands 7962 & 73735: Drug Leads That Inhibit Infection with Plamsodium falciparum, Plasmodium bergei and Plasmodium yoleii
Whitney Smith, Ph.D.
Director, Business Development,Collaborative Drug Discovery Inc., CA, USA
Title: Lessons Learned While Deploying Present and Developing Future Collaborative Informatics Innovations
Ravindra Peravali, Ph.D.
Head, Screening Center,ITG, Karlsruhe Institute of Technology, Germany
Title: Zebrafish as a model organism for drug discovery and testing
Kamil Paruch, Ph.D.
Department of Chemistry, Masaryk University, Czech RepublicTitle: Furo[3,2-b]pyridine – a novel privileged scaffold for highly selective kinase inhibitors and effective modulators of the Hedgehog pathway
Sunil Premawansa, Ph.D.
University of ColomboSri Lanka
Title: Involvement of Angiopoietin 1 and 2 in dengue patients specifically with respect to critical stage of dengue haemorrhagic fever
Adam R. Renslo, Ph.D.
Director of Chemistry, University of California, San Francisco, CA, USATitle: Ferrous Iron Dependent Pharmacology in Cancer and Infectious Disease
Anuradha Roy, Ph.D.
Director, High Throughput Screening LaboratoryUniversity of Kansas, KS, USA
Title: Early Drug Discovery in Academia
Johannes Reynisson, Ph.D.
School of Chemical Sciences, University of Auckland, New ZealandTitle: Virtual Screening for Novel Atg5-Atg16 Complex Inhibitors for Autophagy Modulation
Jikui Song, Ph.D.
University of California, RiversideCA, USA
Title: Perspectives for Zika Virus NS5 Protein as a Drug Target
Paul C. Trippier, Ph.D.
Texas Tech University Health Sciences Center, TX, USATitle: Multi-modal Small Molecule Therapeutic Development for Batten Disease
Susana Valente, Ph.D.
Department of Immunology and Microbiology, The Scripps Research Institute, FL, USATitle: Silencing of the HIV Reservoir with a Potent Tat Inhibitor
Thomas Webster, Ph.D.
Northeastern University, MA, USATitle: Antibiotic resistant bacteria, chemotherapeutic resistant cancer cells: Conventional drug therapy needs a nano face lift
Minhang Xin, Ph.D.
Xi’an Jiaotong University, P.R. ChinaTitle: Novel 6-aryl substituted quinazoline derivatives as potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitors
Weian Zhao, Ph.D.
Sue and Bill Gross Stem Cell Research CenterUniversity of California, Irvine, CA, USA
Title: Targeting Biophysical Cues to Study, Diagnose, and Treat Cancer
Participants
Krishnan Chakravarthy
NanoAxis, LLC.NY, USA
Mukhtar Dauda
Bayero UniversityNigeria
Somlyai Gabor
HYD Pharma Inc.Hungary
Amiram Goldblum
The Hebrew University of JerusalemIsrael
Rajamma Mathew
New York Medical CollegeNY, USA
Alan D. Rogol
University of Virginia Medical SchoolMD, USA
Ram Samudrala
State University of New YorkNY, USA
Anavi-Goffer Sharon
Ariel UniversityIsrael